JP7481721B2 - ヒト肝前駆細胞の調製方法 - Google Patents
ヒト肝前駆細胞の調製方法 Download PDFInfo
- Publication number
- JP7481721B2 JP7481721B2 JP2022117083A JP2022117083A JP7481721B2 JP 7481721 B2 JP7481721 B2 JP 7481721B2 JP 2022117083 A JP2022117083 A JP 2022117083A JP 2022117083 A JP2022117083 A JP 2022117083A JP 7481721 B2 JP7481721 B2 JP 7481721B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- progenitor cells
- hepatic progenitor
- hepatocytes
- differentiated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000000130 stem cell Anatomy 0.000 title claims description 163
- 230000002440 hepatic effect Effects 0.000 title claims description 159
- 241000282414 Homo sapiens Species 0.000 title claims description 102
- 238000000034 method Methods 0.000 title claims description 71
- 210000003494 hepatocyte Anatomy 0.000 claims description 208
- 210000004027 cell Anatomy 0.000 claims description 130
- 238000012360 testing method Methods 0.000 claims description 107
- 239000000126 substance Substances 0.000 claims description 103
- 208000006454 hepatitis Diseases 0.000 claims description 38
- 231100000283 hepatitis Toxicity 0.000 claims description 35
- 210000002966 serum Anatomy 0.000 claims description 34
- 238000012258 culturing Methods 0.000 claims description 25
- 239000003112 inhibitor Substances 0.000 claims description 22
- HIJMSZGHKQPPJS-UHFFFAOYSA-N 3-(6-methylpyridin-2-yl)-n-phenyl-4-quinolin-4-ylpyrazole-1-carbothioamide Chemical compound CC1=CC=CC(C=2C(=CN(N=2)C(=S)NC=2C=CC=CC=2)C=2C3=CC=CC=C3N=CC=2)=N1 HIJMSZGHKQPPJS-UHFFFAOYSA-N 0.000 claims description 19
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 18
- 238000012216 screening Methods 0.000 claims description 16
- 208000019423 liver disease Diseases 0.000 claims description 11
- 229940124597 therapeutic agent Drugs 0.000 claims description 9
- 230000009385 viral infection Effects 0.000 claims description 7
- 206010019799 Hepatitis viral Diseases 0.000 claims description 5
- 201000001862 viral hepatitis Diseases 0.000 claims description 5
- 208000017283 Bile Duct disease Diseases 0.000 claims description 4
- 239000002609 medium Substances 0.000 description 61
- 230000014509 gene expression Effects 0.000 description 33
- 210000004185 liver Anatomy 0.000 description 31
- 108090000790 Enzymes Proteins 0.000 description 29
- 241000700605 Viruses Species 0.000 description 29
- 230000000694 effects Effects 0.000 description 29
- 102000004190 Enzymes Human genes 0.000 description 28
- 229940088598 enzyme Drugs 0.000 description 28
- 210000000013 bile duct Anatomy 0.000 description 24
- 210000002919 epithelial cell Anatomy 0.000 description 24
- 230000002503 metabolic effect Effects 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 22
- 239000012526 feed medium Substances 0.000 description 21
- 238000011579 SCID mouse model Methods 0.000 description 20
- 238000002054 transplantation Methods 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 18
- 230000004060 metabolic process Effects 0.000 description 18
- 102000009027 Albumins Human genes 0.000 description 16
- 108010088751 Albumins Proteins 0.000 description 16
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 14
- 230000004069 differentiation Effects 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 13
- 206010019851 Hepatotoxicity Diseases 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 238000005516 engineering process Methods 0.000 description 13
- 239000012091 fetal bovine serum Substances 0.000 description 13
- 231100000304 hepatotoxicity Toxicity 0.000 description 13
- 230000007686 hepatotoxicity Effects 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- IYOZTVGMEWJPKR-IJLUTSLNSA-N Y-27632 Chemical compound C1C[C@@H]([C@H](N)C)CC[C@@H]1C(=O)NC1=CC=NC=C1 IYOZTVGMEWJPKR-IJLUTSLNSA-N 0.000 description 11
- 239000001963 growth medium Substances 0.000 description 11
- 230000006698 induction Effects 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 238000005138 cryopreservation Methods 0.000 description 9
- XMGJGSKRRWXOIF-UHFFFAOYSA-N 2-(azepan-1-yl)ethyl 2-cyclohexyl-2-thiophen-3-ylacetate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1CCCCC1C(C1=CSC=C1)C(=O)OCCN1CCCCCC1 XMGJGSKRRWXOIF-UHFFFAOYSA-N 0.000 description 8
- 102000018832 Cytochromes Human genes 0.000 description 8
- 108010052832 Cytochromes Proteins 0.000 description 8
- 101000693913 Homo sapiens Albumin Proteins 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 102000004140 Oncostatin M Human genes 0.000 description 8
- 108090000630 Oncostatin M Proteins 0.000 description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- 102000044814 human ALB Human genes 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- LFVPBERIVUNMGV-UHFFFAOYSA-N fasudil hydrochloride Chemical compound Cl.C=1C=CC2=CN=CC=C2C=1S(=O)(=O)N1CCCNCC1 LFVPBERIVUNMGV-UHFFFAOYSA-N 0.000 description 7
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 7
- 229960002963 ganciclovir Drugs 0.000 description 7
- 210000005228 liver tissue Anatomy 0.000 description 7
- 108010082117 matrigel Proteins 0.000 description 7
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 7
- 229960002695 phenobarbital Drugs 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 6
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 101000919359 Homo sapiens Cytochrome P450 2C9 Proteins 0.000 description 6
- 229910021529 ammonia Inorganic materials 0.000 description 6
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 6
- 229960003957 dexamethasone Drugs 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 102000048369 human CYP2C9 Human genes 0.000 description 6
- 238000002350 laparotomy Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 5
- 208000031404 Chromosome Aberrations Diseases 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 5
- 108091000080 Phosphotransferase Proteins 0.000 description 5
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 5
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 231100000005 chromosome aberration Toxicity 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 229960002435 fasudil Drugs 0.000 description 5
- 229960002725 isoflurane Drugs 0.000 description 5
- 229960000381 omeprazole Drugs 0.000 description 5
- 102000020233 phosphotransferase Human genes 0.000 description 5
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 5
- 229960001225 rifampicin Drugs 0.000 description 5
- 239000011435 rock Substances 0.000 description 5
- -1 small molecule compound Chemical class 0.000 description 5
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical group C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 5
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 4
- 108010082126 Alanine transaminase Proteins 0.000 description 4
- 206010007269 Carcinogenicity Diseases 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 4
- 206010008909 Chronic Hepatitis Diseases 0.000 description 4
- 238000008157 ELISA kit Methods 0.000 description 4
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 4
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 description 4
- 206010067125 Liver injury Diseases 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 239000002543 antimycotic Substances 0.000 description 4
- 210000003050 axon Anatomy 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 231100000260 carcinogenicity Toxicity 0.000 description 4
- 230000007670 carcinogenicity Effects 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000009229 glucose formation Effects 0.000 description 4
- 231100000234 hepatic damage Toxicity 0.000 description 4
- 238000012744 immunostaining Methods 0.000 description 4
- 230000008818 liver damage Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000001000 micrograph Methods 0.000 description 4
- 244000309715 mini pig Species 0.000 description 4
- YOVNFNXUCOWYSG-UHFFFAOYSA-N n-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethylimidazo[4,5-c]pyridin-6-yl]oxyphenyl]-4-(2-morpholin-4-ylethoxy)benzamide Chemical compound C1=C2N(CC)C(C=3C(=NON=3)N)=NC2=CN=C1OC(C=1)=CC=CC=1NC(=O)C(C=C1)=CC=C1OCCN1CCOCC1 YOVNFNXUCOWYSG-UHFFFAOYSA-N 0.000 description 4
- 108010003524 sodium-bile acid cotransporter Proteins 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 description 3
- 241000711549 Hepacivirus C Species 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 108010071690 Prealbumin Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000009190 Transthyretin Human genes 0.000 description 3
- 102000016540 Tyrosine aminotransferases Human genes 0.000 description 3
- 108010042606 Tyrosine transaminase Proteins 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 239000007640 basal medium Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 229940043355 kinase inhibitor Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 231100000299 mutagenicity Toxicity 0.000 description 3
- 230000007886 mutagenicity Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000002676 xenobiotic agent Substances 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- CHADEQDQBURGHL-UHFFFAOYSA-N (6'-acetyloxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(OC(C)=O)C=C1OC1=CC(OC(=O)C)=CC=C21 CHADEQDQBURGHL-UHFFFAOYSA-N 0.000 description 2
- BFOPDSJOLUQULZ-GXKRWWSZSA-N (S)-2-methyl-1-(4-methylisoquinoline-5-sulfonyl)-1,4-diazepane dihydrochloride Chemical compound Cl.Cl.C[C@H]1CNCCCN1S(=O)(=O)C1=CC=CC2=CN=CC(C)=C12 BFOPDSJOLUQULZ-GXKRWWSZSA-N 0.000 description 2
- 201000011374 Alagille syndrome Diseases 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 102000001267 GSK3 Human genes 0.000 description 2
- 108060006662 GSK3 Proteins 0.000 description 2
- 102000038624 GSKs Human genes 0.000 description 2
- 108091007911 GSKs Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108010015776 Glucose oxidase Proteins 0.000 description 2
- 239000004366 Glucose oxidase Substances 0.000 description 2
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 2
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 241000709721 Hepatovirus A Species 0.000 description 2
- 101000892398 Homo sapiens Tryptophan 2,3-dioxygenase Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 101150053185 P450 gene Proteins 0.000 description 2
- 108091005682 Receptor kinases Proteins 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 108091005735 TGF-beta receptors Proteins 0.000 description 2
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 2
- 102100040653 Tryptophan 2,3-dioxygenase Human genes 0.000 description 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 230000001857 anti-mycotic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 201000001883 cholelithiasis Diseases 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000007398 colorimetric assay Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 231100000025 genetic toxicology Toxicity 0.000 description 2
- 230000001738 genotoxic effect Effects 0.000 description 2
- 229940116332 glucose oxidase Drugs 0.000 description 2
- 235000019420 glucose oxidase Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- RSAZYXZUJROYKR-UHFFFAOYSA-N indophenol Chemical class C1=CC(O)=CC=C1N=C1C=CC(=O)C=C1 RSAZYXZUJROYKR-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 231100001092 no hepatotoxicity Toxicity 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000008672 reprogramming Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 208000010157 sclerosing cholangitis Diseases 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- VEBWTGYUIBTVNR-MLGOLLRUSA-N (6ar,9r)-n-ethyl-7-methyl-6,6a,8,9-tetrahydro-4h-indolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)NCC)C2)=C3C2=CNC3=C1 VEBWTGYUIBTVNR-MLGOLLRUSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- MQGPSCMMNJKMHQ-UHFFFAOYSA-N 7-hydroxyflavone Chemical class C=1C(O)=CC=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 MQGPSCMMNJKMHQ-UHFFFAOYSA-N 0.000 description 1
- 101150058750 ALB gene Proteins 0.000 description 1
- 102100028161 ATP-binding cassette sub-family C member 2 Human genes 0.000 description 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- 102000018918 Activin Receptors Human genes 0.000 description 1
- 108010052946 Activin Receptors Proteins 0.000 description 1
- 208000005641 Adenomyosis Diseases 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 101150117450 CYP1A2 gene Proteins 0.000 description 1
- 101150069992 CYP2B6 gene Proteins 0.000 description 1
- 101150053096 CYP2C9 gene Proteins 0.000 description 1
- 101150010738 CYP2D6 gene Proteins 0.000 description 1
- 101150116544 CYP3A4 gene Proteins 0.000 description 1
- 101150075266 CYP7A1 gene Proteins 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 206010010317 Congenital absence of bile ducts Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 102000002263 Cytochrome P-450 CYP2C8 Human genes 0.000 description 1
- 108010000561 Cytochrome P-450 CYP2C8 Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 230000008836 DNA modification Effects 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 101710165567 Extracellular signal-regulated kinase 1 Proteins 0.000 description 1
- 101710165576 Extracellular signal-regulated kinase 2 Proteins 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 206010049704 Gallbladder polyp Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000031856 Haemosiderosis Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 241000724675 Hepatitis E virus Species 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 206010019759 Hepatitis chronic persistent Diseases 0.000 description 1
- 208000037262 Hepatitis delta Diseases 0.000 description 1
- 241000724709 Hepatitis delta virus Species 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 102000011787 Histone Methyltransferases Human genes 0.000 description 1
- 108010036115 Histone Methyltransferases Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 206010024652 Liver abscess Diseases 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 208000001940 Massive Hepatic Necrosis Diseases 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- PPQNQXQZIWHJRB-UHFFFAOYSA-N Methylcholanthrene Chemical compound C1=CC=C2C3=CC4=CC=C(C)C(CC5)=C4C5=C3C=CC2=C1 PPQNQXQZIWHJRB-UHFFFAOYSA-N 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
- 102100024192 Mitogen-activated protein kinase 3 Human genes 0.000 description 1
- 102000004855 Multi drug resistance-associated proteins Human genes 0.000 description 1
- 108090001099 Multi drug resistance-associated proteins Proteins 0.000 description 1
- 108010066419 Multidrug Resistance-Associated Protein 2 Proteins 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- NHJSWORVNIOXIT-UHFFFAOYSA-N PD-166866 Chemical compound COC1=CC(OC)=CC(C=2C(=NC3=NC(N)=NC=C3C=2)NC(=O)NC(C)(C)C)=C1 NHJSWORVNIOXIT-UHFFFAOYSA-N 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 101000739513 Rattus norvegicus Secretin Proteins 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 101150064021 TDO2 gene Proteins 0.000 description 1
- 101150091380 TTR gene Proteins 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 101710136122 Tryptophan 2,3-dioxygenase Proteins 0.000 description 1
- 102000057288 Tryptophan 2,3-dioxygenases Human genes 0.000 description 1
- 208000018839 Wilson disease Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- OUGIDAPQYNCXRA-UHFFFAOYSA-N beta-naphthoflavone Chemical compound O1C2=CC=C3C=CC=CC3=C2C(=O)C=C1C1=CC=CC=C1 OUGIDAPQYNCXRA-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 201000005271 biliary atresia Diseases 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000000490 cosmetic additive Substances 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
- 229960003804 efavirenz Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000004039 endoderm cell Anatomy 0.000 description 1
- 201000009274 endometriosis of uterus Diseases 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000010842 high-capacity cDNA reverse transcription kit Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 239000013586 microbial product Substances 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- FMURUEPQXKJIPS-UHFFFAOYSA-N n-(1-benzylpiperidin-4-yl)-6,7-dimethoxy-2-(4-methyl-1,4-diazepan-1-yl)quinazolin-4-amine;trihydrochloride Chemical compound Cl.Cl.Cl.C=12C=C(OC)C(OC)=CC2=NC(N2CCN(C)CCC2)=NC=1NC(CC1)CCN1CC1=CC=CC=C1 FMURUEPQXKJIPS-UHFFFAOYSA-N 0.000 description 1
- DOBKQCZBPPCLEG-UHFFFAOYSA-N n-benzyl-2-(pyrimidin-4-ylamino)-1,3-thiazole-4-carboxamide Chemical compound C=1SC(NC=2N=CN=CC=2)=NC=1C(=O)NCC1=CC=CC=C1 DOBKQCZBPPCLEG-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
- 229940118537 p53 inhibitor Drugs 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 208000013976 polyp of gallbladder Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011897 real-time detection Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- 102000009076 src-Family Kinases Human genes 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 101150098170 tat gene Proteins 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/067—Hepatocytes
- C12N5/0672—Stem cells; Progenitor cells; Precursor cells; Oval cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/407—Liver; Hepatocytes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
Description
項1.ヒト成熟肝細胞を血清、A-83-01及びCHIR99021を含有する培地で培養することを含む、ヒト肝前駆細胞の調製方法。
項2.前記ヒト成熟肝細胞が乳幼児由来である、項1に記載のヒト肝前駆細胞の調製方法。
項3.前記血清がウシ胎児血清である、項1又は2に記載のヒト肝前駆細胞の調製方法。
項4.ヒト成熟肝細胞を血清、A-83-01及びCHIR99021を含有する培地で培養することにより調製された、ヒト肝前駆細胞。
項5.項4に記載されたヒト肝前駆細胞から誘導された成熟肝細胞。
項6.項5に記載された成熟肝細胞を用いることを含む、被検物質のスクリーニング方法。
項7.項5に記載された成熟肝細胞を用いることを含む、肝炎ウイルスの培養方法。
項8.項5に記載された成熟肝細胞が非ヒト哺乳動物に移植された、ヒト肝臓モデル動物。
項9.ヒト肝前駆細胞又は成熟肝細胞を用いて、被検物質の代謝及び/又は肝毒性を評価するためのキットであって、
ヒト成熟肝細胞を血清、A-83-01及びCHIR99021を含有する培地で培養することにより調製されたヒト肝前駆細胞、又は該ヒト肝前駆細胞から誘導された成熟肝細胞を含む、キット。
本発明に使用するヒト成熟肝細胞は、生体肝臓組織から既知の任意の方法にしたがって、取得することができる。なお、本明細書において、生体肝臓組織とは、出生後のヒト肝臓から取得した肝臓組織を意味する。生体肝臓組織の供給個体は、生存していても死亡していてもよい。生体肝臓組織の供給個体の年齢は限定されないが、細胞増殖の観点から、20代以下が好ましく、さらに好ましくは10才以下であり、より好ましくは、乳幼児(0才~7才)であり、最も好ましくは乳児(0才~2才)である。
本発明に用いられる血清は、例えば、ヒト血清、ウシ胎児血清(FBS)、ウシ血清、仔ウシ血清、ヤギ血清、ウマ血清、ブタ血清、ヒツジ血清、ウサギ血清、ラット血清などが挙げられ、好ましくはFBS、仔ウシ血清、ウシ血清であり、さらに好ましくはFBSである。また、本発明に用いられる血清とは、アルブミン(ウシ、ブタ、ヒト、イヌ、ウサギ、ラット、マウス、ニワトリ等)、ヒト血小板溶解物等の血清成分由来の物質であってもよい。本発明に用いられる血清は、市販品であってもよい。
A-83-01(CAS No.909910-43-6)はTGF-βシグナル阻害薬の一種であり、TGF-β type I/activin受容体様キナーゼ(ALK5)、type I activing/nodal受容体キナーゼ(ALK4)、type Inodal受容体キナーゼ(ALK7)を選択的に阻害することができる。A-83-01は、3-(6-メチル-2-ピリジニル)-N-フェニル-4-(4-キノリニル)-1H-ピラゾール-1-カルボチオアミド(3-(6-Methyl-2-pyridinyl)-N-phenyl-4-(4-quinolinyl)-1H-pyrazole-1-carbothioamide)としても公知である。限定はされないが、A-83-01は和光純薬工業株式会社等から入手することができる。
CHIR99021(CAS No.252917-06-9)はGSK-3β(Glycogen Synthase Kinase 3β)阻害剤の一種で、現在最も選択性の高い阻害剤として知られている。CHIR99021は6-[[2-[[4-(2,4-ジクロロフェニル)-5-(5-メチル-1H-イミダゾール-2-イル)-2-ピリミジニル]アミノ]エチル]アミノ]-3-ピリジンカルボニトリル(6-[[2-[[4-(2,4-dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)-2 pyrimidinyl]amino]ethyl]amino]-3-pyridinecarbonitrile)としても公知である。限定はされないが、CHIR99021は和光純薬工業株式会社等から入手することができる。
本発明において、ヒト成熟肝細胞を培養する培地は、さらにROCKインヒビターを含有していてもよい。ここで、ROCKインヒビターとしては、限定はされないが、Y-27632(CAS No. 146986-50-7)、GSK269962(CAS No. 850664-21-0)、Fasudil hydrochloride(CAS No. 105628-07-7)、H-1152(CAS No. 871543-07-6)が例示され、Y-27632が好ましい。Y-27632は選択的かつ強力なROCK(Rho-associated coiled forming kinase/Rho結合キナーゼ)阻害剤である。Y-27632は、トランス-4-[(1R)-1-アミノエチル]-N-4-ピリジニル-シクロヘキサンカルボキサミド(trans-4-[(1R)-1-aminoethyl]-N-4-pyridinyl-cyclohexanecarboxamide)としても公知である。また、Y-27632はフリー体であっても、塩酸塩、硫酸塩等の塩の形であっても、水和物であってもよい。GSK269962Aは、N-[3-[[2-(4-アミノ-1,2,5-オキサジアゾル-3-イル)-1-エチル-1H-イミダゾ[4,5-c]ピリジン-6-イル]オキシ]フェニル]-4-[2-(4-モルフォリニル)エチオキシ]ベンザミド(N-[3-[[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]phenyl]-4-[2-(4-morpholinyl)ethoxy]benzamide)としても公知である。Fasudil hydrochlorideは、ファスジル塩酸塩(1-(5-Isoquinolinesulfonyl)homopiperazine Dihydrochloride)としても公知である。Fasudil hydrochlorideは、フリー体であっても、塩酸塩、硫酸塩等の塩の形であっても、水和物であってもよい。H-1152は、(S)-(+)-2-メチル-1-[(4-メチル-5-イソキノリニル)sulfonyl]-ヘキサハイドロ-1H-1,4-ヂアゼピンヂヒドロクロリド((S)-(+)-2-Methyl-1-[(4-methyl-5-isoquinolinyl)sulfonyl]-hexahydro-1H-1,4-diazepine dihydrochloride)としても公知である。限定はされないが、Y-27632は和光純薬工業株式会社等、SK269962AはAxon medchem社等、Fasudil hydrochlorideはTocris Bioscience社等、H-1152は和光純薬工業社等から入手することができる。
培養温度:15℃~45℃が好ましく、25℃~40℃がさらに好ましく、37℃が最も好ましい。
CO2濃度:1%~10%が好ましく、3%~8%がさらに好ましく、5%が最も好ましい。
培養期間:1日(24時間)~30日が好ましく、3日~20日がさらに好ましい。
ヒト凍結肝細胞(Lot.ID:HC3-14、45Y、Male、Caucasian、Xenotech社製)を、解凍用培地(William’s E培地(Life Technologies社製、32551-020)、10% FBS(Life Technologies社製)、10-4M insulin(Sigma社製)、1x antibiotic/antimycotic solution(Life Technologies社製))に懸濁し、500rpm(約40xg)、4℃、2minの低速遠心にてヒト肝細胞回収した。回収した細胞を播種培地(L-15培地(Life Technologies社製、11415-064)、1x antibiotic/antimycotic solution (Life Technologies社製))に再度懸濁し、細胞数をカウントした。コラーゲンコートプレート(IWAKI社製)に、1x104 cells/cm2となるように播種し、CO2インキュベーター(37℃、5%CO2)内に入れ、細胞が接着した3-5時間後に播種培地から、基礎培地(以下、「SHM培地」(DMEM/F12培地(Life Technologies社製、11320033)、5mM HEPES(Sigma社製、St. Louis、 MO)、30mg/L L-proline(Sigma社製)、0.05% BSA(Sigma社製)、10ng/mL epidermal growth factor(Sigma社製)、insulin-transferrin-serine(ITS)-X(Life Technologies社製)、10-7M dexamethasone(Dex)(Sigma社製)、10mM nicotinamide(Sigma社製)、100mM ascorbic acid-2 phosphate(Wako社製)、1x antibiotic/antimycotic solution(Life Technologies社製))に、10% FBS(Life Technologies社製)、0.5μM A-83-01(WAKO社製)及び3μM CHIR99021(Axon Medchem社製)を加えたAC-F培地、基礎培地に10% FBS(Life Technologies社製)、0.5μM A-83-01(WAKO社製)、3μM CHIR99021(Axon Medchem社製)及び10μM Y-27632(WAKO社製)を加えたYAC-F培地、及び0.5 μM A-83-01(WAKO社製)、3μM CHIR99021(Axon Medchem社製)及び10μM Y-27632(WAKO社製)を加えたYAC培地に置き換えた。その後は2-3日に一回の頻度で各試験用培地を用いて培地交換を行い、CO2インキュベーター(37℃、5%CO2)内で培養を行った。
実施例1と同様にヒト凍結肝細胞(10M、Female、Hispanic、Celsis社製)を用いて、AC-F培地で培養を行ったところ、6日後(D6)、9日後(D9)及び12日後(D12)において、肝前駆細胞が観察された(図2)。図2において、矢印は肝前駆細胞から、一部自発的に分化し成熟化した細胞を示す。
実施例1と同様にヒト凍結肝細胞(2Y、Male、Caucasian、Biopredic社製)を用いて、AC-F培地で培養を行ったところ、7日、及び14日後において、肝前駆細胞が観察された。これに対して、試験培地を10% FBS(Life Technologies社製)のみを含有するFBS培地として、培養を行った場合には、肝前駆細胞は観察されなかった(図3)。
uPA遺伝子が肝細胞特異的に発現し、先天的に肝臓が障害を受け続けることで慢性肝障害を発症するcDNA-uPA/SCIDマウスに、本発明の肝前駆細胞の移植を行い、cDNA-uPA/SCIDマウスの肝臓に、本発明の肝前駆細胞由来の肝細胞が生着することを確認する。
肝細胞特異的にtimidine kinaseを発現するため、ガンシクロビル投与によって肝細胞特異的に細胞死を誘導し、肝障害を引き起こすことができる、TK-NOG mouseに本発明の肝前駆細胞の移植を行い、TK-NOG mouseの肝臓に、本発明の肝前駆細胞由来の肝細胞が生着することを確認する。
肝細胞へ分化されたことを確認する遺伝子発現の試験
実施例1と同様にヒト凍結肝細胞を用いて、AC-F培地で培養を行い、肝前駆細胞を調製した後に、oncostatin M(OSM)及びデキサメサゾン(Dex)を含む培地で6日間培養を行い、その後マトリゲルで培養を行い、肝細胞へ分化させる。分化させた肝細胞について、取扱説明書に従って、SurePrint G3 Rat GE 8x60K Kit(G4853A)及びSurePrint G3 Mouse GE 8x60K Ver 2.0 Kit(G4852B)を用い、one-color microarray-based gene expression analysis system(Agilent Technologies社製)によりデータを取得する。強度数値は2を底として対数変換して、Partek Genomics Suite 6.6(Partek Inc製、 Chesterfield、MO、USA)にデータを読み込む。遺伝子発現の解析にはone-way ANOVAを用い、発現に差のある遺伝子を同定する。それぞれの解析において、P値及び変化量の比を算出する。Partek Genomics Suite 6.6を用い、全データセット又はソート済みのデータセットについて、選択したプローブセットを用いたEuclidean distances of average linkage clusteringの手法によって、Unsupervised clustering及びヒートマップ作成を実施し、肝特異的遺伝子の発現の確認を行う。
セクレチンアッセイ
実施例1と同様にヒト凍結肝細胞を用いて、AC-F培地で培養を行い、肝前駆細胞を調製した後に、mTeSR1及びYACを含む培地で、MEF上で、6日間培養を行い、その後2%マトリゲルを添加して2日間培養を行い、胆管上皮細胞へ分化させる。分化させた胆管上皮細胞について、ラットセクレチンを2x10-7 M(Wako社製)にて添加して30分培養したのち、位相差顕微鏡を用いて、胆管様構造における管腔領域の拡大を観察して、胆管上皮細胞への分化の確認を行う。
フルオレセインジアセテートアッセイ
実施例7と同様に、肝前駆細胞から胆管上皮細胞へ分化させ、得られた胆管上皮細胞にフルオレセインジアセテートを添加して、15分培養したのち、新しい培地に交換する。さらに30分間培養を継続することで分解されたフルオレセインの管腔領域への輸送を促す。そののち、培地をHBSS(+)に置換し、蛍光顕微鏡にてフルオレセインの分布を観察して、胆管上皮細胞への分化の確認を行う。
肝細胞へ分化させた際の肝特異的遺伝子の発現の確認試験
実施例6と同様に、肝前駆細胞から肝細胞へ分化させ、得られた肝細胞についてmiRNeasy Mini Kit (QIAGEN社製、 Venlo、 The Netherlands)を用い、トータルRNAを抽出する。取扱説明書に従って、High-Capacity cDNA Reverse Transcription Kit (Life Technologies社製)を用いて逆転写を行う。作製したcDNAを鋳型に、Platinum SYBR Green qPCR SuperMix UDG (Invitrogen社製)を用いてPCRを行い、肝特異的遺伝子の発現の確認を行う。
実施例1と同様にヒト凍結肝細胞(10M、Female、Hispanic、Celsis社製)を用いて、AC-F培地で11日間培養を行った細胞について、PBS(-)で2回洗浄した後に、TrypLE Express(Thermo社製、 SKU:12604013)にて剥離回収して、細胞数の測定を行った。細胞懸濁液を遠心(200xg、5分)した後、5x107cellsになるように、DMEM10(10%FBS-DMEM)に懸濁した。
実施例10と同様にヒト凍結肝細胞(10M、Female、Hispanic、Celsis社製)を用いて、AC-F培地で11日間培養を行った細胞について、PBS(-)で2回洗浄した後に、TrypLE Express(Thermo社製、 SKU:12604013)にて剥離回収して、細胞数の測定を行った。細胞懸濁液を遠心(200xg、5分)した後、5x107cellsになるように、DMEM10(10%FBS-DMEM)に懸濁した。TK-NOG mouse(Hasegawa et. al.、 2011、7-8週齢、インビボサイエンス社製、n=2)にガンシクロビル(GCV)を投与し、投与1週間後にALTを測定して400-1600 U/dLの値を示した個体を被移植動物として使用した。なおGCV の調製に当たっては500 mg(田辺三菱製薬、点滴静注用デノシン)を10 mLの注射用蒸留水(大塚)で溶解(50 mg/mL)し、0.2mLずつ分注したものをオリジナルストックとし、移植時にこれをPBS(-)で5倍希釈したものを用事調製し、マウス体重10gあたり0.1mLを腹腔内投与して、肝細胞特異的に細胞死を誘導した。TK-NOG mouseをイソフルラン麻酔下にて開腹し、脾臓を露出し、1x106 cells/mouseで投与した後、開腹部を縫合した。1週間に1回、20~40uLの血液を尾静脈から採取して、血清を分離して、血清中のhuman特異的なアルブミンをALB Human ALB ELISA kit(Bethyl社製、商品コード:E88-129)で測定した。図8に示すようにマウス血清中human ALBが存在することが確認でき、肝前駆細胞由来の肝細胞が生着することが確認された。なお、細胞投与後60日における血清中human ALBは、それぞれの個体で8.1mg/mL及び2.2mg/mLであった。
実施例1同様にヒト凍結肝細胞1(10M、Female、Hispanic、Celsis社製)及びヒト凍結肝細胞2(8M、Male、Caucasian、BioreclamationIVT社製)を用いて、AC-F培地で培養を行い、肝前駆細胞(それぞれ「FCL」、「DUX」と言う)を調製した後に、oncostatin M(OSM、5ng/ml)及びデキサメサゾン(Dex、10-6M)を含む培地で6日間培養を行い、その後マトリゲルで2日間培養を行い、肝細胞へ分化させた。肝前駆細胞及び分化させた肝細胞について、メタノール(MeOH、1%濃度)及びオメプラゾール(OMP、50 μM)を用いて、代謝酵素CYP1A2の活性の測定を行った。また、蒸留水及びフェノバルビタール(1 mM)を用いて、代謝酵素CYP3A4の活性の測定を行った。代謝酵素の活性は、プロメガ社のLuciferin1A2キット及び、Luciferin-IPAキットによりそれぞれ行った。肝前駆細胞を肝細胞に分化させることにより、CYP1A2及びCYP3A4が誘導されることが明らかとなった(図11~14)。
実施例1と同様にヒト凍結肝細胞(10M、Female、Hispanic、Celsis社製)を用いて、AC-F培地で培養を行い、肝前駆細胞を調製した後に、oncostatin M(OSM、5ng/ml)及びデキサメサゾン(Dex、10-6M)を含む培地で6日間培養を行い、その後マトリゲルで2日間培養を行い、肝細胞へ分化させた。肝前駆細胞及び分化させた肝細胞について、PCRを用いて、各代謝酵素等の発現量を測定した。肝前駆細胞を肝細胞に分化させることにより、ALB、TAT、TDO2、TTR、G6PC、NTCP、CYP1A2、CYP2B6、CYP2C9、CYP2C19、CYP2D6、CYP3A4及びCYP7A1が誘導されることが明らかとなった(図15~27)。
実施例1と同様にヒト凍結肝細胞(10M、Female、Hispanic、Celsis社製)を用いて、肝前駆細胞を調製した後に、cDNA-uPA/SCIDマウス(2-4M、Male、フェニクスバイオ社製)をイソフルラン麻酔下にて開腹し、脾臓を露出し、0.5x105~2x106 cells/mouseで移植した後、開腹部を縫合した。移植後73日目に、肝臓を摘出して肝細胞をかん流分離し、4x105 cells/wellで24穴コラーゲンプレート(IWAKI社製)上で2%FBS-SHM培地を用いて4日間培養を行った。図28及び図29はそれぞれ、移植前の肝前駆細胞及び移植後取り出し、4日間培養を行った細胞の写真であり、形態学的な観察から、移植された細胞がマウス肝臓内で完全に肝細胞へと成熟している様子がうかがえた。
実施例1と同様にヒト凍結肝細胞(8M、Male、Caucasian、BioreclamationIVT社製)を用いて、肝前駆細胞を調製し、実施例14と同様に移植及び培養を行った。図32及び図33はそれぞれ、移植前の肝前駆細胞及び移植後取り出し、4日間培養を行った細胞の写真である。
実施例1と同様にヒト凍結肝細胞(1Y、Male)を用いて、肝前駆細胞を調製し、実施例14と同様に移植及び培養を行った。図36及び37はそれぞれ、移植前の肝前駆細胞及び移植後取り出し、4日間培養を行った細胞の写真である。
Claims (4)
- ヒト肝前駆細胞を用いた被検物質のスクリーニング方法であって、
ヒト成熟肝細胞を血清、A-83-01及びCHIR99021を含有する培地で培養してヒト肝前駆細胞を調製する工程、並びに、当該ヒト肝前駆細胞に対して、被験物質を接触させる工程を含む、方法。 - 更に、被検物質を接触させた前記細胞の機能を測定することを含む、請求項1に記載の方法。
- 更に、被検物質を接触させた前記細胞の機能を亢進させる物質を選択することを含む、請求項1又は2に記載の方法。
- 前記スクリーニングが、肝疾患または胆管疾患の治療剤のスクリーニング、肝炎ウイルス感染阻害剤のスクリーニング、又は、ウイルス性肝炎治療剤のスクリーニングである、請求項1~3のいずれか1項に記載の方法。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016212285 | 2016-10-28 | ||
JP2016212285 | 2016-10-28 | ||
JP2018547784A JP7134416B2 (ja) | 2016-10-28 | 2017-10-27 | ヒト肝前駆細胞の調製方法 |
PCT/JP2017/038907 WO2018079714A1 (ja) | 2016-10-28 | 2017-10-27 | ヒト肝前駆細胞の調製方法 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018547784A Division JP7134416B2 (ja) | 2016-10-28 | 2017-10-27 | ヒト肝前駆細胞の調製方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022132606A JP2022132606A (ja) | 2022-09-08 |
JP7481721B2 true JP7481721B2 (ja) | 2024-05-13 |
Family
ID=62025202
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018547784A Active JP7134416B2 (ja) | 2016-10-28 | 2017-10-27 | ヒト肝前駆細胞の調製方法 |
JP2022117083A Active JP7481721B2 (ja) | 2016-10-28 | 2022-07-22 | ヒト肝前駆細胞の調製方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018547784A Active JP7134416B2 (ja) | 2016-10-28 | 2017-10-27 | ヒト肝前駆細胞の調製方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20190302100A1 (ja) |
EP (1) | EP3533865A4 (ja) |
JP (2) | JP7134416B2 (ja) |
CN (1) | CN109890956A (ja) |
WO (1) | WO2018079714A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102107602B1 (ko) * | 2017-05-29 | 2020-05-08 | 한양대학교 산학협력단 | 인간 성체 간세포 리프로그래밍 배지 조성물 |
CN117802031A (zh) * | 2018-09-30 | 2024-04-02 | 中国科学院分子细胞科学卓越创新中心 | 肝细胞的体外扩增培养方法及应用 |
US20210403874A1 (en) * | 2018-10-15 | 2021-12-30 | Evia Life Sciences Inc. | Method for Producing Stem/Precursor Cells, By Using Low Molecular Weight Compound, From Cells Derived From Endodermal Tissue or Organ |
JP7284985B2 (ja) * | 2019-03-29 | 2023-06-01 | 国立大学法人 長崎大学 | 肝前駆細胞を含む細胞集団を製造する方法 |
CA3142666A1 (en) * | 2019-06-04 | 2020-12-10 | University Health Network | Methods of making and using liver cells |
CN110358683B (zh) * | 2019-07-25 | 2022-04-26 | 中国科学院电工研究所 | 一种生物反应器自动控制装置 |
KR102375161B1 (ko) * | 2020-03-24 | 2022-03-16 | 한국원자력의학원 | 섬유화 질환 치료용 복합 약학 조성물 |
CN112522178B (zh) * | 2020-11-27 | 2023-05-16 | 上海市东方医院(同济大学附属东方医院) | 一种在体外长期培养和扩增成熟肝细胞的方法 |
WO2023069949A1 (en) * | 2021-10-18 | 2023-04-27 | Evia Life Sciences Inc. | Compositions and methods of use thereof for treating liver fibrosis |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006254896A (ja) | 2005-01-07 | 2006-09-28 | Effector Cell Institute Inc | ヒト肝細胞様細胞およびその利用 |
WO2013018851A1 (ja) | 2011-08-02 | 2013-02-07 | 独立行政法人国立がん研究センター | 誘導肝幹細胞から肝分化誘導する方法及び誘導肝前駆細胞 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101368924B1 (ko) | 2005-11-17 | 2014-03-04 | 니뽄젠야쿠코교 가부시키가이샤 | 세포 보존용 수용액 |
CN101275121B (zh) * | 2007-03-26 | 2011-05-11 | 芦银雪 | 体外培养扩增的人肝脏祖先细胞及其制备方法 |
RU2010139426A (ru) * | 2008-03-17 | 2012-04-27 | Зе Скрипс Ресеч Инститьют (Us) | Комбинация химического и генетического подходов к получению индуцированных плюрипотентных стволовых клеток |
NO2373784T3 (ja) * | 2008-12-17 | 2018-03-24 | ||
WO2011009294A1 (zh) * | 2009-07-23 | 2011-01-27 | 北京华源博创科技有限公司 | 通过诱导分化获得肝脏细胞、肝脏内胚层细胞和肝脏前体细胞的方法 |
CA3194845A1 (en) * | 2009-10-16 | 2011-04-21 | The Scripps Research Institute | Induction of pluripotent cells |
KR102482184B1 (ko) * | 2010-12-22 | 2022-12-28 | 페이트 세러퓨틱스, 인코포레이티드 | 단세포 분류 및 iPSC의 증강된 재프로그래밍을 위한 세포 배양 플랫폼 |
US9512406B2 (en) * | 2013-12-20 | 2016-12-06 | The J. David Gladstone Institute, a testamentary trust established under the Will of J. David Gladstone | Generating hepatocytes |
CN105154386B (zh) * | 2014-05-30 | 2018-04-24 | 中国人民解放军第二军医大学东方肝胆外科医院 | 人肝细胞长期维持和增殖传代培养的专用培养基和培养方法 |
AU2017205801A1 (en) * | 2016-01-08 | 2018-08-16 | Cynity Co., Ltd. | Method for producing hepatic stem/precursor cells from mature hepatic cells using low-molecular-weight compound |
-
2017
- 2017-10-27 US US16/301,166 patent/US20190302100A1/en not_active Abandoned
- 2017-10-27 JP JP2018547784A patent/JP7134416B2/ja active Active
- 2017-10-27 CN CN201780066190.9A patent/CN109890956A/zh active Pending
- 2017-10-27 WO PCT/JP2017/038907 patent/WO2018079714A1/ja unknown
- 2017-10-27 EP EP17866130.2A patent/EP3533865A4/en active Pending
-
2022
- 2022-07-22 JP JP2022117083A patent/JP7481721B2/ja active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006254896A (ja) | 2005-01-07 | 2006-09-28 | Effector Cell Institute Inc | ヒト肝細胞様細胞およびその利用 |
WO2013018851A1 (ja) | 2011-08-02 | 2013-02-07 | 独立行政法人国立がん研究センター | 誘導肝幹細胞から肝分化誘導する方法及び誘導肝前駆細胞 |
Non-Patent Citations (1)
Title |
---|
Cell Stem Cell,2014年,Vol. 14,pp. 561-574 |
Also Published As
Publication number | Publication date |
---|---|
EP3533865A1 (en) | 2019-09-04 |
JPWO2018079714A1 (ja) | 2019-09-19 |
JP7134416B2 (ja) | 2022-09-12 |
CN109890956A (zh) | 2019-06-14 |
JP2022132606A (ja) | 2022-09-08 |
WO2018079714A1 (ja) | 2018-05-03 |
EP3533865A4 (en) | 2020-04-15 |
US20190302100A1 (en) | 2019-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7481721B2 (ja) | ヒト肝前駆細胞の調製方法 | |
Kim et al. | Small molecule-mediated reprogramming of human hepatocytes into bipotent progenitor cells | |
Marongiu et al. | Hepatic differentiation of amniotic epithelial cells | |
Baxter et al. | Generating hepatic cell lineages from pluripotent stem cells for drug toxicity screening | |
US20180305669A1 (en) | Microtissue formation using stem cell-derived human hepatocytes | |
WO2016148216A1 (ja) | 肝細胞及び肝非実質細胞、並びにそれらの調製方法 | |
EP3401392B1 (en) | Method for producing hepatic stem/precursor cells from mature hepatic cells using low-molecular-weight compound | |
JP7556502B2 (ja) | ヘパトサイトの作製方法 | |
US20220233605A1 (en) | Methods of making and using liver cells | |
US10093903B2 (en) | Production of virus-receptive pluripotent stem cell (PSC)-derived hepatocytes | |
US20050148073A1 (en) | Induction of hepatocyte proliferation in vitro by inhibition of cell cycle inhibitors | |
Schmelzer et al. | Hepatic stem cells and the liver’s maturational lineages: Implications for liver biology, gene expression, and cell therapies | |
JP2020533025A (ja) | 肝疾患および機能不全を処置するための組成物および方法 | |
WO2020203753A1 (ja) | 肝前駆細胞を含む細胞集団を製造する方法 | |
WO2023160671A1 (zh) | 诱导性成熟肝脏细胞及其制备的方法 | |
KR102610435B1 (ko) | 간 오가노이드를 기반으로 하는 윌슨병 모델의 제조방법 및 이의 용도 | |
US11566229B2 (en) | Expansion and maintenance of adult primary human hepatocytes in culture | |
WO2014004784A1 (en) | Generation of hepatocytes from pluripotent stem cells | |
Owens | Engineering a three-dimensional culture system for the directed differentiation of pluripotent stem cells toward a hepatocyte-like cell fate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20220810 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220816 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220816 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220810 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20230628 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230628 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230725 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230925 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231124 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240126 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240219 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240417 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240418 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7481721 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |